

Maria Beatrice BilÃ²

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6857162/publications.pdf>

Version: 2024-02-01

40
papers

2,439
citations

331670

21
h-index

315739

38
g-index

40
all docs

40
docs citations

40
times ranked

2010
citing authors

#	ARTICLE	IF	CITATIONS
1	EAAACI guidelines: Anaphylaxis (2021 update). Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 357-377.	5.7	193
2	Platelet-activating factor acetylhydrolase: A biomarker in Hymenoptera venom allergy?. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1032-1035.	5.7	5
3	Use of face masks and allergic rhinitis from ragweed: Why mention only total pollen count and not air pollution levels?. International Forum of Allergy and Rhinology, 2022, 12, 886-888.	2.8	1
4	Allergen Content of Therapeutic Preparations for Allergen-Specific Immunotherapy of European Paper Wasp Venom Allergy. Toxins, 2022, 14, 284.	3.4	7
5	Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry. Journal of Allergy and Clinical Immunology, 2021, 147, 653-662.e9.	2.9	40
6	Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 902-905.	5.7	37
7	Treating venom allergy during COVID-19 pandemic. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 949-950.	5.7	5
8	Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hypercholesterolemia Represent Risk Factors for Severe Anaphylaxis in Hymenoptera Venom-Allergic Subjects over 50 Years Old. International Archives of Allergy and Immunology, 2021, 182, 146-152.	2.1	6
9	Diagnosing, managing and preventing anaphylaxis: Systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1493-1506.	5.7	40
10	Safety and Adherence to Venom Immunotherapy During COVID-19 Pandemic. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 702-708.	3.8	7
11	Wheat Anaphylaxis in Adults Differs from Reactions to Other Types of Food. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2844-2852.e5.	3.8	28
12	Prevalence of Pol d 1 Sensitization in Polistes dominula Allergy and Its Diagnostic Role in Vespidae Double-Positivity. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3781-3787.	3.8	7
13	Use of face masks and allergic nasal symptoms: Why not mention pollen count and air pollution data?. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2021, , 103363.	1.3	0
14	Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 433-436.	5.7	14
15	Antigen 5 Allergens of Hymenoptera Venoms and Their Role in Diagnosis and Therapy of Venom Allergy. Current Allergy and Asthma Reports, 2020, 20, 58.	5.3	25
16	High long-term efficacy of venom immunotherapy after discontinuation. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1793-1796.	5.7	2
17	Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes. Frontiers in Immunology, 2020, 11, 579409.	4.8	29
18	Risk Factors and Characteristics of Biphasic Anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3388-3395.e6.	3.8	35

#	ARTICLE	IF	CITATIONS
19	Shedding Light on the Venom Proteomes of the Allergy-Relevant Hymenoptera <i>Polistes dominula</i> (European Paper Wasp) and <i>Vespula</i> spp. (Yellow Jacket). <i>Toxins</i> , 2020, 12, 323.	3.4	14
20	Fatal anaphylaxis in Italy: Analysis of cause-of-death national data, 2004-2016. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2644-2652.	5.7	22
21	A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2399-2401.	3.8	5
22	Venom immunotherapy in Europe and the United States. <i>Allergo Journal International</i> , 2020, 29, 29-37.	2.0	2
23	Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control?. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.6	2
24	Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice?. <i>International Archives of Allergy and Immunology</i> , 2019, 180, 142-143.	2.1	0
25	Anaphylaxis in Elderly Patients-Data From the European Anaphylaxis Registry. <i>Frontiers in Immunology</i> , 2019, 10, 750.	4.8	47
26	Large local reactions to Hymenoptera stings: Outcome of re-stings in real life. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1969-1976.	5.7	25
27	Idiopathic anaphylaxis. <i>Clinical and Experimental Allergy</i> , 2019, 49, 942-952.	2.9	28
28	Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1368-1372.	3.8	49
29	Safety of a 2-day ultrarush immunotherapy in vespid allergic patients. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 130-132.	1.0	2
30	CAP-Inhibition, Molecular Diagnostics, and Total IgE in the Evaluation of <i>Polistes</i> and <i>Vespula</i> Double Sensitization. <i>International Archives of Allergy and Immunology</i> , 2018, 177, 365-369.	2.1	21
31	Efficacy of a single dose of omalizumab for the prevention of ethylene oxide intraoperative anaphylaxis. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 249-250.	1.0	2
32	High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: A real-life experience. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 327-329.e1.	3.8	22
33	International consensus on (ICON) anaphylaxis. <i>World Allergy Organization Journal</i> , 2014, 7, 9.	3.5	360
34	2012 Update. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 389-399.	2.3	236
35	Honeybee Venom Immunotherapy: A Comparative Study Using Purified and Nonpurified Aqueous Extracts in Patients with Normal Basal Serum Trypsin Concentrations. <i>Journal of Allergy</i> , 2012, 2012, 1-6.	0.7	10
36	World Allergy Organization anaphylaxis guidelines: Summary. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 587-593.e22.	2.9	491

#	ARTICLE	IF	CITATIONS
37	Purified vs. nonpurified venom immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2010, 10, 330-336.	2.3	23
38	Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: The importance of baseline serum tryptase. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 105-111.e5.	2.9	175
39	Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: Importance of baseline serum tryptase—a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 1047-1054.	2.9	386
40	The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts. <i>Annals of Allergy, Asthma and Immunology</i> , 2009, 103, 57-61.	1.0	36